シミュレイション内科　リウマチ・アレルギー疾患を探る

出版社： 永井書店
著者：
発行日： 2005-04-25
分野： 臨床医学：内科  >  アレルギー
ISBN： 4815917167
電子書籍版： 2005-04-25 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,350 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,675 円(税込)

購入する

商品紹介

医学生・研修医そして専門医を目指す内科医を対象に，「リウマチ・アレルギー性疾患」について，各疾患の中から代表的な状況をシュミレイション症例によって提供する．総論では，両疾患が免疫応答の異常によって引き起こされる疾患群としての特徴を持つことに注目．疾患編では，実際の診療にあたり，診断の重要性を強調．また，モノクローナル抗体を中心とした生物学的製剤と言われる分子標的療法の開発によって，膠原病・リウマチ性疾患が最も刺激的で魅力に満ちた臨床領域の一つだと言われるようになった現状も紹介する．

目次

  • シミュレイション内科　リウマチ・アレルギー疾患を探る

    ―目次―

    総論
    1．リウマチ性疾患の診察
    2．免疫疾患の疾患感受性遺伝子
    3．自己免疫応答と組織障害
    4．炎症に関わる分子とその制御　関節リウマチを中心に
    5．アレルギー関与する分子
    6．リウマチ診療の臨床検査
    7．アレルギー診療での臨床検査
    8．膠原病・リウマチ性疾患に使われる治療薬　
    　　　生物学的製剤を中心として
    9．アレルギー疾患に用いられる治療薬

    疾患編
    1．抗核抗体が陽性なら膠原病か？
    2．かゆくない皮疹・かゆい皮疹
    3．SLE患者が胸痛を訴えた！　どうする？
    4．SLE患者が発熱と汎血球減少症を呈した！　何を考えるか？
    5．SLE、抗リン脂質抗体症候群の経過中に発熱、
    　　貧血および血小板減少が出現
    6．蛋白尿を呈したSLE患者は腎生検が必要！？　
    ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.6 掲載の参考文献
1)高杉 潔:関節所見の取り方. リウマチ性疾患へのアプローチ.参天製薬2003.
 
P.10 掲載の参考文献
1) Hugot JP, Chamaillard M, Zouali H, et al:Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603, 2001.
PubMed
2) Ogura Y, Bonen DK, Inohara N, et al:A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-6, 2001.
PubMed
3) Horikawa Y, Oda N, Cox NJ, et al:Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 26:163-75, 2000.
PubMed
4) Van Eerdewegh P, Little RD, Dupuis J, et al:Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418:426-30, 2002.
PubMed
5) Prokunina L, Castillejo-Lopez C, Oberg F, et al:A regulatory polymorphism in PDCDI is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666-9, 2002.
 
6) Okamoto K, Makino S, Yoshikawa Y, et al:Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am J Hum Genet 72:303-12, 2003.
PubMed
7) Suzuki A, Yamada R, Chang X, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
8) Tokuhiro S, Yamada R, Chang X, et al:An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:341-8, 2003.
 
9) Tsuchiya N, Ohashi J, Tokunaga K:Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev 190:169-181, 2002.
PubMed
10) Gregersen PK, Silver J, Winchester RJ:The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-13, 1987.
PubMed
11) Graham RR, Ortmann WA, Langefeld CD, et al:Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet 71:543-53, 2002.
PubMed
12) Shirakawa T, Deichmann KA, Izuhara K et al:Atopy and asthma;genetic variants of IL-4 and IL-13 signaling. Immunol Today 21:60-4, 2000.
 
13) Heinzmann A, Mao X-Q, Akaiwa M, et al:Genetic variants of IL-13 signaling and human asthma and atopy. Hum Mol Genet 9:549-59, 2000.
PubMed
14) Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al:Association of Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus;Contribution of FCGR2B to the genetic susceptibility to SLE. Arthritis Rheum 46:1242-1254, 2002.
 
15) Siriboonrit U, Tsuchiya N, Sirikong M, et al:Association of Fcγ receptor IIB, IIIA and IIIB polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens 61:374-383, 2003.
 
16) Chu ZT, Tsuchiya N, Kyogoku C, et al:Association of Fcγ receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese;a common susceptibility gene in the Asian populations. Tissue Antigens 63:21-7, 2004.
 
17) Kyogoku C, Tsuchiya N, Wu H, et al:Association of Fcγ receptor IIA, but not of IIB and IIIA, polymorphisms with systemic luptls erythematosus. A family-based association study in Caucasians. Arthritis Rheum 50:671-3, 2004.
 
18) Kyogoku C, Kono H, Tsuchiya N, et al:SLE-assoiated polymorphism of Fcγ IIB IIe 232 Thr affects localization at lipid rafts and attenuation of BCR signaling. Arthritis Rheum 48 (Suppl):S647, 2003.
 
P.16 掲載の参考文献
1) Suzuki A, Yamada R, Chang X, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
2) Tokuhiro S, Yamada R, Chang X, et al:An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:341-348, 2003.
 
3) Nishimura H, et al:Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151,1999.
PubMed
4) Nishimura H, et al:Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322, 2001.
PubMed
5) Sakaguchi N, Takahashi T, Hata H, et al:Altered thymic T-cell selection odue to a mutation of the ZAP^70 gene causes autoimmune arthritis in mice. Nature 426:454-460, 2003.
PubMed
6) Rajewsky K:Burnet's unhappy hybrid. Nature 394:624-625, 1998.
 
7) Matsumoto I, et al:Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-1735, 1999.
 
8) Matsumoto I, et al:How antigodies to a ubiquitous cytoplasmic enzyme may proboke joint-specific autoimmune disease. Nature Immunol 3:360-365, 2002.
 
9) Takayanagi H, Ogasawara K, Hida S, et al:T cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-g. Nature 408:600-605, 2000.
PubMed
P.22 掲載の参考文献
1) Feldmann M, Brennan FM, Maini RN:Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440, 1996.
PubMed
2) Lohning M, Richter A, Radbruch A:Cytokine memory of T helper lymphocytes. Adv Immunol 80:115-81, 2002.
PubMed
3) Grogan JL, Locksley RM:T helper cell differentiation on again, off again. Curr Opin Immunol 14:366-72, 2002
PubMed
4) Murphy PM:International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Phamacol Rev 54:227-9, 2002.
 
5) IUIS/WHO Subcommittee on Chemokine Nomenclature:Chemokine/chemokine receptor nomenclature. Cytokine 21:48-9, 2003.
PubMed
6) Bacon K, Baggiolini M, Broxmeyer H, et al:IUIS/WHO Subcommittee on Chemokine Nomenclature:Chemokine/chemokine receptor nomenclature. J lnterferon Cytokine Res 22:1067-8, 2002.
 
7) Szekanecz Z, Kim J, Koch AE:Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 15:15-21, 2003.
 
8) Bevilacqua MP:Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767-804, 1993.
PubMed
P.25 掲載の参考文献
1) Prescott SL, Macaubas C, Smallacombe T, et al:Development of allergen-specific T-cell memory in atopic and normal children. Lancet 353:196-200, 1999.
PubMed
2) Strachan DP:Hay fever, hygiene, and household size. BMJ 299:1259-1260, 1989. Matricardi PM, Rosmini F, Riondino S, et al:Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma:epidemiological study. BMJ 320:412-417, 2000.
 
3) Gereda JE, Leung DY, Thatayatikom A, et al:Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 355:1680-3, 2000.
PubMed
4) Seki Y, Inoue H, Nagata N, et al, Suppressor of cytokine signaling-3 (SOCS3) regulates onset and maintenance of type 2 helper T cell mediated allergic responses. Nat Med 9:1047-1054, 2003.
PubMed
5) Zuany-Amorim C, Sawicka E, Manlius C, et al:Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 8:625-629, 2002.
PubMed
6) Wills-Karp M, Santeliz J, Karp CL:The germless theory of allergic disease:revisiting the hygiene hypothesis. Nat Rev Immunol 1:69-75, 2001.
PubMed
7) Maizels RM, Yazdanbakhsh M, Immune regulation by helminth parasites:cellular and molecular mechanisms. Nat Rev Immunol 3:733-744, 2003.
PubMed
8) Jutel M, Watanabe T, Klunker S, et al:Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413:420-425, 2001.
PubMed
9) Iikura Y, Naspitz CK, Mikawa H, et al:Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 68:233-236, 1992.
PubMed
10) Matsuoka T, Hirata M, Tanaka H, et al:Prostaglandin D2 as a mediator of allergic asthma. Science 287:2013-2017, 2000.
PubMed
11) Hirai H, Tanaka K, Yoshie O, et al:Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255-261, 2001.
 
12) Grunig G, Warnock M, Wakil AE, et al:Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263, 1998.
PubMed
13) Wills-Karp M, Luyimbazi J, Xu X, et al:Interleukin-13:central mediator of allergic asthma. Science 282:225 & 2261, 1998.
 
14) Chibana K, Ishii Y, Asakura T, et al:Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. J Immunol 170:4290-4295, 2003.
PubMed
15) Leckie MJ, ten Brinke A, Khan J, et al:Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet 356:2144-2148, 2000.
PubMed
16) Nakajima T, Matsumoto K Suto H, et al:Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probearrays:Abundant expression of major basic protein in mast cells. Blood 98:1127-1134, 2001.
PubMed
17) Flood-Page P, Menzies-Gow A, Phipps S, et al:Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029-1036, 2003.
PubMed
18) Panettieri RA, Tan EM, Ciocca V, et al:Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression and contraction In vitro:differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 19:453-461, 1998.
 
19) Brightling CE, Bradding P, Symon FA, et al:Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:1699-1705, 2002.
PubMed
20) Bradding P:The role of the mast cell in asthma:a reassessment. Curr Opin Allergy Clin Immunol 3:45-50, 2003.
PubMed
P.30 掲載の参考文献
1) 吉田 浩:膠原病又はその類縁疾患. DRG/PPS対応臨床検査のガイドライン2002 (第4次案). 日本臨床検査医学会編89-92, 2002.
 
2)山中 寿:血清MMP-3 (matrix metaloproteinase-3). 日本臨牀60:2325-2330, 2002.
 
3) 高崎 芳成:抗トポイソメラーゼI抗体 抗セントロメア抗体. 日本内科学会雑誌92:1927-1931, 2003.
 
4) Tan E M, Feltkamp T E, Smolen J S, et al:Range of antinuclear antibodies in "healthy" individuals. Arthritis & Rheumatism 40:1601-1611, 1997.
PubMed
5) Mazanec DJ, Kantor SM:Systemic Lupus Erythematosusu. In Diagnostic Strategies for Common Medical Problems (Black ER ed), pp419-428, Philadelphia, PA, American College of Physicians-American Society of Internal Medicine, 1999.
 
6) McFarlane I G:Autoimmune Hepatitis:The investigational and clinical challenges. American Association for the Study of Liver Diseases 8:107-112, 1999.
 
7) Rantapaa-Dahlvust S, de Jong B A W, Berglin E, et al:Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predicit the development of rheumatoid arthritis. Arthritis & Rheumatism 48:2741-2749, 2003.
 
P.35 掲載の参考文献
1) 石川哮, 中川武正:検査法総論-IgE検査法. 臨床アレルギー学改訂第2版 (監修宮本昭正). 南江堂pp178-192, 1998.
 
2) 田中良一, 山本一彦:アレルギーの臨床に必要な検査の常識-成人の場合. JIM 13:115-118, 2003.
 
P.39 掲載の参考文献
1) Ginzler EM, Aranow C, Buyon J, et al:A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis. Arthritis Rheum S647, 2003.
 
2) Cavagna L, Caporali R, Epis O, et al:Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheum 19:329-31, 2001.
 
3) Chaudhari U, Romano P, Mulcahy L, et al:Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomised trial. Lancet 357:9271, 2001.
PubMed
4) Steinfeld SD, Demols P, Salmon I, et al:Infliximab in patients with primary Sjogren's syndrome. A pilot study. Arthritis Rheum 44:2371-75, 2001.
PubMed
5) Yee A M, Pochapin M B:Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 135:27-31, 2001.
PubMed
6) Kallenberg C G, Cohen Tervaert J W:New treatments of ANCA-associated vasculitis. Sarcoidosis Vasculitis & Diffuse Lung Diseases 17:125-9, 2000.
 
7) Pisetsky DS:Tumor necrosis factorablockers and the induction of anti-ds DNA autoantibodies. Arthritis Rheum 43:2381-2, 2000.
PubMed
8) Aringer M, Steiner G, Graninger W, et al:Role of tumor necrosis factoraand potential benefit of Tumor necrosis factorablockade treatment in systemic lupus erythematosus, comment on the editorial by Piestsky. Arthritis Rheum 44:1721-2, 2001.
PubMed
9) Stone JH, Uhlfelder ML, Hellmann DB, et al:Etanercept combined with conventional treatment in Wegener's granulomatosis. a six-month open-label trial to evaluate safety. Arthritis Rheum 44:1149-54, 2001.
PubMed
10) Elaine Husni M, Maier AL, Mease PJ, et al:Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46:1171-1176, 2002.
 
11) Utz JP, Limper AH, Kalra S, et al:Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177-85, 2003.
PubMed
12) Gottenberg J-E, Merle-Vincent F, Bentaberry F, et al:Anti-tumor necrosis factor therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A follow-up report of tolerability and efficacy. Arthritis Rheum 48:2019-2024, 2003.
 
13) Kremer JM, Westhovens R, Leon M, et al:Treatment of Rheumatoid Arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Eng J Med 349:1907-15, 2003.
PubMed
14) Schneider P, et al:BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-56, 1999.
PubMed
15) Moore PA, et al:BLyS; member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-3, 1999.
 
16) Mackay F, et al:Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-710, 1999.
PubMed
17) Yu G, et al:APRIL and TALL-I and receptors BCMA and TACI. System for regulating humoral immunity. Nat Immunol 1:252-6, 2000.
 
18) Thompson JS, et al:BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108-11, 2001.
 
19) Waldschmidt TJ, et al:Long live the mature B cell-a baffling mystery resolved. Science 293:2012-3, 2001.
PubMed
20) Gross JA, et al:TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-9, 2000.
 
21) Zhang J, et al:Cutting edge:a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10, 2001.
 
22) Cheema GS, et al:Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-9, 2001.
PubMed
23) Suzuki K, et al:Molecular mechanism of BAFF expression in peripheral blood lymphocytes in systemic lupus erythematosus patients. Arthritis Rheum 44:S99, 2001.
 
24) Furie R, Stohl W, Ginzler E, et al:Safety, pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (Human monoclonal antibody to BlyS) in SLE patients. Arthritis Rheum 48:S377, 2003.
 
P.48 掲載の参考文献
1) 厚生省免疫 アレルギー研究班:喘息予防 管理ガイドライン1998改訂第2版 (牧野荘平ほか編), 協和企画通信, 2003.
 
2) アレルギー診療ガイドライン作成委員会:鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症 (改訂第4版), 東京, ライフサイエンス, 2002.
 
3) 木花 光:ステロイド外用剤. 皮膚外用剤, その適応と使い方 (原田敬之編), pp25-43, 東京, 南山堂, 2002.
 

疾患編

P.55 掲載の参考文献
1) Tan E M:Antinuclear antibodies:Diagnostic markers for autoimmundiseases and probes for cell biology. Adv. Immunol 44:93-151, 1989.
 
2) 高崎 芳成:自己抗体とその臨床的意義. Annual Review免疫1992 (菊地 浩吉, 矢田 純一, 奥村 康編), pp266-277, 東京, 中外医学社, 1992.
 
3) 高崎 芳成:膠原病の診断基準をどのように使うか. Medical Practice 20:550-557, 2003.
Medical*Online
4) Tan EM, Feltkamp TEW, Smolen JS, et al:Range of antinuclear antibodies in "Healthy" individuals. Arthritis Rheum 40:1601-1611, 1997.
 
P.61 掲載の参考文献
1) Sontheimer RD:Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 11:475-482, 1999.
PubMed
2) Bohan A, et al:A computerassisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255-286, 1977.
PubMed
3) Kovacs SO, et al:Dermatomyositis. J Am Acad Dermatol 39:899-920, 1998.
PubMed
4) Bohan A, et al:Polymyositis and dermatomyositis. N Engl J Med 292:344-347, 1975.
PubMed
5) Rockerbie NR. et al:Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20:629-632, 1989.
PubMed
P.66 掲載の参考文献
1) D'Cruz D, Khamashta M, Hughes G:Cardiovascular manifestation of systemic lupus erythematosus. In Dubois' lupus erythematosus (6th edition), ed. by Wallace DJ and Hahn BH (Lippincott Williams & Wilkins), pp 645-661, 2002.
 
2) 松本美富士:膠原病の心病変. 日内会誌85:1833-1839, 1996.
 
3) 熊谷俊一, 中村知子:全身性エリテマトーデスの薬物治療. 臨床免疫学会雑誌25:14-20, 2002.
 
4) Bruce IN, Urowitz MB, Gladman DD, et al:Risk actors for coronary heart disease in women with systemic lupus erythematosus. Arthritis Rheum 48:3159-3167, 2003.
 
5) D'Cruz D, Khamashta M, Hughes G:Pulmonary manifestation of systemic lupus erythematosus. In Dubois' lupus erythematosus (6th edition), ed. by Wallace DJ and Hahn BH (Lippincott Williams & Wilkins), pp663-683, 2002.
 
6) 猪熊茂子:膠原病の肺病編. 内科80:79-85, 1997.
 
P.71 掲載の参考文献
1) Wong KF, et al:The acute lupus hemophagocytic syndrome. Ann Intern Med 114:387-390, 1991.
PubMed
2) Kumakura S, et al:autoimmune-associated hemophagocytic syndrome. Am J Med 102:113-115, 1997.
PubMed
3) Papo T, et al:The spectrum of reactive hemophagocytic syndrome in systemic lupus erythmatosus. J Rheumatol 26:927-930, 1999.
 
4) Stepp SE, et al:Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 289:1957, 1999.
 
5) Prahalad S, et al:Rtanercept in the treatment of macrophage activation sundrome. J Rheumatol 28:120, 2001.
 
P.76 掲載の参考文献
1) Lahita RG (ed):Systemic Lupus Erythematosus 3rd edition, Academic Press, 1999.
 
2) Khamashta MA (ed):Hughes Syndrome; Antiphospholipid Syndrome, Springer-Verlag, 2000.
 
3) Wilson WA, et al:International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop. Arthritis Rheum 42.7:1309-11, 1999.
PubMed
4) Bukowski RM, et al:Thrombotic thrombocytopenic purpura:a review. Prog Hemost Thromb:287-337, 1982.
PubMed
5) Atsumi T, et al:Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43. 9:1982-93, 2000.
PubMed
P.81 掲載の参考文献
1) Austin HA III, Balow JE:Treatent of lupus nephritis. Semin Nephrol 20:265-276, 2000.
 
2) Fiehn C, Hajjar Y, Mueller K, et al:Improved clinical outcome of lupus nephritis during the past decade:importance od early diagnosis and treatment. Ann Rheum Dis 62:435-439, 2003.
 
3) Balow JE, Boumpas DT, Austin HA:Systemic lupus erythemsatosus and the kidney. In systemic lupus erythematosus 3rd edition (ed by Lahita RG):657-685, 1999.
 
4) 神田浩子, 三村俊英:ループス腎炎EBMに基づく臨床データブック. 臨床医増刊号27:1431-1437, 2001.
 
5) Lewis EJ, Hunsicker LG, Lan SP, et al:A controlled trial of plasmapheresis therapy in severe lupus nephritis New. Engl J Med 326:1373-1379, 1992.
PubMed
6) Cortes-Hernandez J, Ordi-Ros J, Labrador M, et al:Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 12:287-296, 2003.
PubMed
P.87 掲載の参考文献
1) ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599-608, 1999.
 
2) Sanna G, Bertolaccini ML, Mathieu A:Central nervous system lupus:a clinical approach to therapy. Lupus 12:935-942, 2003.
PubMed
3) Denburg SD, Denburg JA:Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 12:883-890, 2003.
PubMed
P.94 掲載の参考文献
1) Buyon JP:Systemic lupus erythematosus. Clinical and laboratory features (in Klippel JH eds):Primer on the Rheumatic Diseases, 12th ed, pp335-346, Atlanta, the Arthritis Foundation, 2001.
 
2) Hay EM:Systemic lupus erythematosus:Bailliere Clin Rheum 9:437-470, 1995.
 
3) 橋本博史:SLEの活動性指標. 医学のあゆみ 176:277-283, 1996.
Medical*Online
4) 高崎芳成:SLEの活動性評価. 医学のあゆみ 191:994-999, 1999.
Medical*Online
5) Bombardier C, Gladman DD, Urowitz MB, et al:Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992.
PubMed
6) Symmons DPM, Coppock JS, Bacon PA, et al:Development of a computerised index of clinical disease activity in systemic lupus erythematosus. Q J Med 69:927-937, 1988.
 
7) Liang MH, Socher SA, Larson MG, et al:Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989.
PubMed
8) 横張龍一:厚生省特定疾患自己免疫疾患調査研究班 (班長:恒松徳五郎) 昭和60年度研究報告書:p50-57, 1986.
 
9) Hellmann DB, Petri M, Whiting-O'keefe Q:Fatal infections in systemic lupus erythematosus:the role of opportunistic organisms. Medicine 66:341-347, 1987.
PubMed
P.98 掲載の参考文献
1) Arnett FC, Edworthy SM, Bloch DA, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
2) 山本純巳, 柏崎禎夫, 延永正:日本リウマチ学会による早期慢性関節リウマチの診断基準-2診断基準の作成-. リウマチ 34:1013-1018, 1994.
 
3) 近藤啓文, 小林茂人, 田中清介, ほか:日本リウマチ学会による早期慢性関節リウマチの診断基準-3診断基準の検証-. リウマチ40:54-59, 2000.
 
4) American College of Rheumatology Subcommittee on Rheumatoid Arthritis G:Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 46:328-346, 2002,
 
5) Kroot EJ, de Jong BA, van Leeuwen MA, et al:The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831-1835, 2000.
PubMed
6) Yamanaka H, Matsuda Y, Tanaka M, et al:Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858, 2000.
PubMed
P.104 掲載の参考文献
1) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 46:328-346, 2002.
PubMed
2) Anderson JJ et al:Factors predicting response to treatment in rheumatoid arthritis:the importance of disease duration. Arthritis Rheum 43:22-29, 2000.
PubMed
3) Rich E et al:Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 26:259-261, 1999.
PubMed
4) Mottonen T et al:Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894, 2002.
PubMed
5) Lard LR et al:Early and aggressive treatment of rheumatoid arthritis patients affects the association of JLA class II antigens with progression ofjoint damage. Arthriotis Rheum 46:32&346, 2002.
 
P.111 掲載の参考文献
1) Tanoue LT:Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 19:667-685, 1998.
 
2) Oyama T, Kohno N, Yokoyama A, et al:Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUCI mucin. Lung 175:379-385, 1997.
 
3) Anaya JM, Diethelm L, Ortiz LA, et al:Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24:242-254, 1995.
PubMed
4) Schnabel A, Richter C, Bauerfeind S, et al:Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 52:377-379, 1997.
PubMed
5) Alarcon GS, Kremer JM, Macaluso M, et al:Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127:356364, 1997.
 
6) 瀬戸口京吾, 猪熊茂子:慢性関節リウマチに合併する疾患とその対策. 肺疾患 内科78:235-239, 1996.
 
7) Nicholson AG, Colby TV, et al:The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213-2217, 2000.
PubMed
P.116 掲載の参考文献
1) Henrick Sjogren:Zur Kenntnis Keratoconjunctivitis sicca. Acta Ophthalmol. Suupl. II:1-151, 1933.
 
2) 若井健志ほか:シェーグレン症候群 成人ステイル病の全国疫学調査成績, 厚生省特定疾患難病の疫学調査研究班平成6年度 研究業績集. pp34-40, 1995.
 
3) 藤林孝司ほか:シェーグレン症候群改訂診断基準, 厚生省特定疾患免疫疾患調査研究班平成10年度研究報告書, pp 135-138, 1999.
 
4) 菅井 進ほか:シェーグレン症候群に発症する固形癌とリンパ系腫瘍, 厚生省特定疾患免疫疾患調査研究班平成6年度研究報 告書, pp146-148, 1995.
 
P.121 掲載の参考文献
1) 針谷正祥:多発性筋炎 皮膚筋炎. EBMをいかす膠原病 リウマチ診療 (鎌谷直之監修), pp112-123, 東京, メジカルビュー社, 2000.
 
2) Hirakata M, Nagai S:Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501-508, 2000.
PubMed
3) Targoff NI:Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12:475-481, 2000.
 
4) 原まさ子:多発性筋炎 皮膚筋炎の治療.リウマチ39:670-678, 1999.
 
P.125 掲載の参考文献
1) Bohlmeyer TJ, Wu AH, Perryman MB:Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 20:845-856, 1994.
PubMed
2) Bohan A, Peters JB, Bowman RL, et al:A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56:255, 1977.
 
3) Zuckner J:Drug-related myopathies. Rheum Dis Clin North Am 20:1017-1032, 1994.
PubMed
P.129 掲載の参考文献
1) 吉藤 元, 藤井降夫, 三森経世, ほか:多発性筋炎 皮膚筋炎における自己抗体と治療反応性 臨床経過の検討. 日本内科学会雑誌 92:150, 2003.
 
2) Euwer RL, Sontheimer RD:Amyopathic dermatomyositisa review. J Invest Dermatol 100:124S-127S, 1993.
 
3) Olsen NJ, Park JH, King LE Jr:Amyopathic derlnatomyositis. Curr Rheumatol Rcp 3:346-351, 2001.
 
4) 吉藤 元, 三森経世:[EBMのための内科疾患データファイル]多発性筋炎/皮膚筋炎「内科」 89:1373-1377, 2002.
 
5) Bohan A, Peter JB:Polymyositis and dermatomyositis. N Engl J Med 292:344-347, 1975.
PubMed
P.133 掲載の参考文献
1) Bird HA, et al:An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434-439, 1979.
PubMed
2) Nobunaga M, et al:Clinical studies of polymyalgia rheumatica. A proposal of diagnostic criteria. Jpn J Med 28:452-456, 1989.
PubMed
3) 西岡淳一, ほか:わが国におけるリウマチ性多発筋痛症の病態調査と日本人における診断基準確立の必要性への示唆. リウマチ 25:265-273, 1985.
 
P.142 掲載の参考文献
1) 桑名正隆, 佐藤伸一, 近藤啓文, ほか:全身性強皮症患者の評価. リウマチ 42; 22:654-665, 2002.
 
2) 近藤啓文, 遠藤平仁:強皮症腎病態と治療, 胃と透析51:50-53, 2001.
 
3) Steen VD, Medsger TA:Long-Term outcome of scleroderma renal crisis, Ann Intern Med 133:600-603, 2000.
PubMed
4) Endo H, Hosono T, Kondo H:Antineutrophilic cytoplasmic auto antibodies in 6 patients with remal failure and systemic sclerosis. J Rheumatol 21:864-870, 1994.
 
5) Helfrich DJ, Bauner B, Steen VD, et al:Normotensive renal crisis in systemic sclerosis. Artritis Rheum 32:1128-1134, 1989.
 
P.147 掲載の参考文献
1) Jennette JC, Falk RJ:Clinical and pathological classification of ANCA-associated vasculitis:What are controversies? Clin Exp Immunol 101 (Suppl 1):18-26, 1995.
 
2) 難治性血管炎の診療マニュアル. 厚生科学研究特定疾患対策研究事業難治性血管炎に関する調査研究班 (班長:橋本博史) 発行, 2002.
 
3) Jennette JC, Falk RJ:Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 13 (Suppl1):1620, 1998.
 
4) Xiao H, Heeringa P, Hu P, et al:Anti neutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause plomeru-lonephritis and vasculitis in mice. J Clin Invest 110:955-963, 2002.
 
5) Jayne DWR (EUVAS):Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13:48-55, 2001.
 
6) de Groot K, Adu D, Savage COS (EUVAS):The value of pulse cyclophosphamide in ANCA-associated vasculitis:meta-analysis and critical review. Nephrol Dial Transplant 16:2018-2027, 2001.
 
P.153 掲載の参考文献
1) Churg J, Strauss L:Allergic granuromatosis, allergic angitis and periarteritis nodosa. Am J Pathol 27:277, 1951.
 
2) 吉田雅治:ANCA関連血管炎. リウマチ科19:575, 1998.
 
3) 津坂憲政:難病の診断と治療指針改訂版2, 厚生労働省健康局疾病対策研究会編. pp42-46, 東京, 六法出版, 2001.
 
4) Gary SH:血管炎, リウマチ入門 第11版 (日本語版), アメリカ関節炎財団編, 日本リウマチ学会日本語編集, 東京, YMI INC, 1999.
 
5) 深澤千賀子:アレルギー性肉芽腫性血管炎. Evidence Based Medicineを活かす膠原病 リウマチ診療. pp262-263, 東京, メジカルビュー社, 2000.
 
6) 三森明夫:アレルギー性肉芽腫性血管炎, 膠原病診療ノート. pp246-247, 東京, 日本医事新報社, 1999.
 
7) Lhote F, Cohen P, Guillevin L:Polyarteritis nodosa, microscopic polyangitis and Churg-Strauss syndrome. Lupus 7:238-258, 1998.
PubMed
8) Lanham JG, Elkon KB, Pusey CD, et al:Systemic vasculitis with asthma and eosinophilia:a clinical approach to the Churg-Strauss syndrome. Medicine 63:65-81, 1984.
 
9) Cohen P, et al. and the French Polyarteritis Nodosa Study Group:Arthritis Rheum 38 (suppl 9):S391, 1995.
 
10) 塩沢俊一:ANCA. 膠原病学. pp379-382, 東京, 丸善株式会社, 2003.
 
11) 吉田雅治:抗好中球細胞質抗体 (ANCA). 日本内科学会雑誌92:1941-1947, 2003.
 
12) 鈴木和男:ANCA関連血管炎の発症機序. リウマチ科29:228-236, 2003.
 
P.159 掲載の参考文献
1) Savage CO, Harper L, Holland M:New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheurnatol 14:15, 2002.
PubMed
2) Cockwell P, Brooks CJ, Adu D, et al:Interleukin-8:Apathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999.
 
3) Savage CO:ANCA-associated renal vasculitis. Kidney Int:1614-1627, 2001.
PubMed
4) Rarok AA, Stegeman CA, Limburg PC, et al:Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 13:2232, 2002.
PubMed
P.163 掲載の参考文献
1) Choe YH, et al:Takayasu arteritis:Assessment of disease activity with contrast-enhanced MR imaging. Am J Roent 175:505 511, 2000.
 
2) Tso E, et al:Takayasu arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 46:1634-1642, 2002.
PubMed
3) Maeda H, et al:Carotid lesions detected by B-mode ultrasonography in Takayasu arteritis. "Macaroni-sign" as an indicator of the disease. Ultrasound in Med & Biol 17:695-701, 1991.
 
4) Meller J, et al:Value of F-18 FDG hybrid camera PET and MRI in early takayasu aortitis. Eur Radiol 13:400405, 2003.
 
P.167 掲載の参考文献
1) Salvarani C, Cantini F, Boiardi L, et al:Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261-271, 2002.
PubMed
2) Gonzalez-Gay MA, Garcia-Porrua C, Vanquez-Caruncho M, et al:The spectrum of polymyalgia rheumatica in northwestern Spain:incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 26:1326-1332, 1999.
 
3) Bird HA, Esselinckx W, Dixon AS, et al:An elvaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434-439, 1979.
 
4) Chuang TY, Hunder GG, Ilstrup DM, et al:Polymyalgia rheumatica:a 10-year epidemiologic and clinical study. Ann Intern Med 97:672-680, 1982.
PubMed
5) Healey LA:Long term follow-up of polymyalgia rheumatica:evidence for synovitis. Semin Arthritis Rheum 13:322-328, 1984.
PubMed
6) Hunder GG, Bloch DA, Michel BA, et al:The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122-1128, 1990.
PubMed
7) Weyand CM, Goronzy JJ:Arterial wall injury in giant cell arteritis. Arthritis Rheum 42:844-853, 1999.
PubMed
8) Cantini F, Niccoli L, Salvarani C, et al:Treatment of longstanding active giant cell arteritis with infliximab report of four cases. Arthritis Rheum 44:2933-2935, 2001.
PubMed
P.171 掲載の参考文献
1) Hirohata S, Kikuchi H:Behcet's disease. Aethritis Research & Therapy 5:139-146, 2003.
 
2) 広畑 俊成:神経ベーチェット病の病態. 臨床神経 41:1147-1149, 2001.
 
3) Hirohata S, Isshi K, Oguchi H, et al:Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome. Clin Immunol lmmunopathol 82:12-17, 1997.
PubMed
4) Hirohata S, Suda H, Hashimoto T:Low-dose weekly methotrexate for progressive neuropychiatric manifestations in Behcet's disease. J Neurol Sciences 159:181-185, 1998.
 
5) Kikuchi H, Aramaki K, Hirohata S:Low dose MTX for progressive Neuro-Behcet's disease:A follow-up study for 4 years. Adamantiades-Behcet's disease AEMB 528:575-578, 2003.
 
P.176 掲載の参考文献
1) Bywaters EG:Ann Rheum Dis 30:121-133, 1971.
PubMed
2) Ohta A, Yamaguchi M, Kaneoka H, et al:Adult Still's disease:review of 228 cases from the literature. J Rheumatol 14:1139-1146, 1987.
PubMed
3) Yamaguchi M, Ohta A, Tsunematsu T, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430, 1992.
 
4) 大田明英, 宮坂信之:成人スティル病治療指針マニュアル. 厚生省自己免疫疾患調査 研究班, 1996.
 
5) Ohta A, Yamaguchi M, Tsunematsu T, et al:Adult Still's disease:a multicenter survey of Japanese patients. J Rheumatol 17:1058-1063, 1990.
 
6) Pouchot J, Sampalis JS, Beaudet F, et al:Adult Still's disease:manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118-136, 1991.
PubMed
7) Pouchot J, Ouakil H, Debin ML, et al:Adult Still's disease associated with acute human parvovirus B19 infection. Lancet 341:1280-1281, 1993.
PubMed
8) 鐘江 大, 多田芳史, 大田明英, ほか:成人Still病患者のガリウムシンチグラフィにおける骨髄への集積. リウマチ 42:872-878, 2002.
 
9) Fautrel B, Le Moel G, Saint-Marcoux B, et al:Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 28:322-329, 2001.
PubMed
10) Rogers JT:Ferritin translation by interleukin-1 and interleukin-6:the role of sequences upstream of the start codons of the heavy and light subunit gene. Blood 87:2525-2537, 1996.
PubMed
P.187 掲載の参考文献
1) 厚生省免疫 アレルギー研究班:喘息予防 管理ガイドライン1988改訂第2版 (牧野荘平他監修), 東京, 協和企画, 2003.
 
P.192 掲載の参考文献
1) Szczeklik A, Stevenson DD:Aspirin-induced asthma:Advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111:913-912, 2003.
PubMed
2) 谷口正実, 榊原博樹, 末次 勸:成人喘息の診断, アスピリン喘息. 成人気管支喘息の診断と治療 (宮本昭正ほか編), pp141-158, 東京, 現代医療社, 1995.
 
3) 榊原博樹, 末次 勧:アスピリン喘息, 呼吸 12:990-995, 1993.
 
4) 谷口正実, 東 憲孝, 秋山一男:管理治療の実際;アスピリン喘息 (泉 孝英編), 新しい診断と治療のABC 2喘息, pp181-191, 大阪, 最新医学社, 2001.
 
5) Szczeklik A, et al:Clinical patterns of hypersensitivity to nonsteroidal anti-inflamatory drugs and their pathogenesis. J Allergy Clin Immunol 60:276-284, 1977.
 
6) 谷口正実, 東 憲孝ら:アスピリン過敏症に関する最近の話題. Allergy Update 15, 4:1-3, 2003.
 
7) Namazy JA, Simon RA:Sensitivity to nonsteroidal anti-inflamatory drugs. Ann Allergy Asthma Immunol 89:542-540, 2003.
 
8) 末次 勸, 谷口正実, 榊原博樹:アスピリン喘息と性差 (宮本昭正ほか編), 気管支喘息と性, pp89-97, 東京, ライフサイエンス出版, 1996.
 
9) Szczecklik A, Nizankowska E, Duplaga M, et al:Natural history of aspirin-induced asthma. AIANE investigators. Europian Network on aspirin-induced asthma, Eur Respir J 16:432-436, 2000.
 
10) Szczeklik A, Sanak M:The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 32:339-342, 2002.
PubMed
11) 谷口正実, 東 憲孝, 秋山一男:アスピリン喘息の誘発試験の方法. アレルギーの臨床 22:566-570, 2002.
 
12) 谷口正実:アスピリン喘息における静注ステロイド薬の使い方. アレルギーの臨床 23:741-743, 2003.
 
13) 妹川史朗, 佐藤篤彦, 谷口正実ほか:クロモグリク酸ナトリウムは発作寛解期のアスピリン喘息患者に対して急性気管支拡張効果を有する. アレルギー 41:1515-1518, 1992.
Medical*Online
14) 谷口正実, 東憲孝, 東愛ほか:アスピリン喘息の新展開, 最新医学 58:257-263, 2003.
Medical*Online
15) 谷口正実:喘息診療のピットフォール. アスピリン喘息. 日経メディカル9月号:145-148, 2002.
 
16) Smith CM, et al:Urinary leukotriene E4 in bronchial asthma. Eur Respir J 5:693-697, 1992.
PubMed
17) Kawagishi Y, Mita H, et al:Leukotrien C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 109:936-942, 2002.
 
18) Higashi N, Taniguchi M, et al:J Allergy Clin Immunol, in press, 2004.
 
19) Sanak M, et al:Leukotrien C4 synthase promoter polymorphism and risk of aspirin-induced asthma, Lancet 350:1599-1600, 1997.
PubMed
20) Van Sambeek R, et al:5' flanking region polymorphism of the gene encoding leukotriene C4 synthase dose not corerelate with the aspirin-intolelant asthma phenotype in the United States. J Allergy Clin Immunol 106:72-76, 2000.
 
21) Cowburn AS, et al:Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 15, 101:834-846, 1998.
 
23) Berges-Giemo MP, et al:Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Imunol 111:180-186, 2003.
 
24) Sousa AR, et al:Leukotriene-receptor expression on nasal mucosal inflamatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 7:347, 1493-1499, 2002.
 
25) 谷口正実, 後藤範夫, 小林 光ほか:アスピリン喘息患者の治療法は?ファーマナビゲーター アレルギーシリーズ, 喘息編 (足立満監修, 森川昭廣編集), pp330-339, メディカルレビュー社, 2003.
 
P.198 掲載の参考文献
1) 可部順三郎:カンジタによるPIE Syndromeの一症例. 日本胸部疾患学会雑誌 12:683-690, 1974.
 
2) Akiyama K, Greenberger PA, Patterson R, et al:Allergic Bronchopulmonary Candidiasis. Chest 85:699-701, 1984.
PubMed
3) 森晶夫, 谷口正実, 秋山一男:アレルギー性気管支肺アスペルギルス症, 医学のあゆみ別冊:463-466, 2003.
 
4) 蛇沢 晶, 倉島篤行, 斉木茂樹ら:気管支肺アスペルギルス症の病理形態. 結核 72:109-118, 1996.
 
5) Stevens DA, Platts-Mills TAE, DeGraff AC, et al:A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. N E JM 342:756-762, 2000.
 
P.203 掲載の参考文献
1) Mackowiak PA, et al:Drug fever. A critical appraisal of conventional concepts. Ann Intern Med 106:728-733, 1987.
 
2) 高藤 繁:Drug Fever. アレルギーの臨床. 5:997-100, 1998.
 
3) 柏崎 禎夫:薬剤熱Drug Fever. JJSHP 24:1343-1346, 1998.
 
4) 村中 正治:薬剤アレルギー. 臨床アレルギー学 (宮本昭正ほか編). pp402-414, 東京, 1992.
 
P.207 掲載の参考文献
1) Hashimoto K, Yasukawa M, Tohyama M:Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 3:255-260, 2003.
PubMed
2) 橋本公二:Stevens-Johnson症候群, toxic epidermal necrolysis (TEN) とhypersensitivity syndromeの診断基準および治療指 針の研究. 厚生科学特別研究事業平成13年度総括研究報告, 2002.
 
3) Fujino Y, Nakajima M, Inoue H, et al:Human Herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 51:771-774, 2002.
PubMed
4) Masaki T, Fukunaga A, Tohyama M, et al:Human herpesvirus 6 encephalitis in an allopurinol hypersensitivity syndrome. Acta Derm Venereol 83:128-131, 2003.
 
5) Descamps V, Collot S, Houhou N, et al:Human herpesvirus-6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 53:280, 2003.
PubMed
6) Sekine N, Motokura T, Oki T, et al:Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 285:1153-1154, 2001.
 
P.211 掲載の参考文献
1) Host A, Halken S, Jacobsen HP, et al:Clinical course of cow's milk protein allergy/intolerance and atopic diseases in childhood. Pediatr Allergy Immunol 13 (Suppl 15):23-28, 2002.
 
P.217 掲載の参考文献
1) Warshaw EM:Latex allergy. J Am Acad Dermatol 39:1-24, 1998.
PubMed
2) http://www.umin.ac.jp/fukusayou/adr113e.htm
 
3) http://www.umin.ac.jp/fukusayou/h0329-1_15. html
 
4) 大砂博之, 池澤善郎:果物 野菜 穀物アレルゲンとcrossreacting carbohydrate determinantes. アレルギー 免疫:910-919, 2001.
 
5) Dreborg S, Foucard T:Allergy to apple, carrot and potato in children with birch pollen allergy. Allergy 38:167-172, 1983
PubMed

書評

最近チェックした商品履歴

Loading...